GALAPAGOS - Waiting for Santa!
While positive efficacy and safety data from the small PhII, Proof-of-Concept (PoC) study (36 pts) of GLPG0634 (an oral JAK1 inhibitor, RA) justifies GLPG’s optimism about a partnership by YE11, commercial success of it will depend on the strength of the partner’s ability to carve a position in the crowded JAK inhibitor space. GLPG has several partnerships for drug and novel target Discovery; however, its own pipeline still lacks ... For more detail, please read our report released on 22nd November on GLPG titled “Waiting for Santa”!
COMPANIES MENTIONED
GALAPAGOS
GALAPAGOS
